CATB - Catabasis Pharmaceuticals, Inc.
| Previous Close | 8.12 |
| Open | 8.05 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 7.66 - 8.05 |
| 52 Week Range | 0.39 - 18.10 |
| Volume | 113,001 |
| Avg. Volume | 222,453 |
| Market Cap | 90.356M |
| Beta (3Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.12 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.67 |
- Zacks•14 days ago
Top Ranked Momentum Stocks to Buy for April 12th
Top Ranked Momentum Stocks to Buy for April 12th
- Business Wire•25 days ago
Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the 12th UK Neuromuscular Translational Research Conference and the 2019 Muscular Dystrophy Association ...
- Zacks•last month
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
- Zacks•last month
Will Catabasis Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Catabasis.
- Zacks•last month
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
- Zacks•last month
Rising P/E an Overlooked Criterion: 5 Top Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT
Q4 2018 Catabasis Pharmaceuticals Inc Earnings Call
- Zacks•last month
Catabasis (CATB) Beats Earnings in Q4, Revenues Nil
Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.
- Business Wire•last month
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress
-- Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys with Duchenne Muscular Dystrophy --
- Business Wire•last month
Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 8:00am ET at the Westin New York Grand Central Hotel in New York City, NY.
- Zacks•2 months ago
Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards?
Townsquare's (TSQ) fourth-quarter 2018 results are expected to benefit from higher political revenues.
- Zacks•2 months ago
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
- Zacks•2 months ago
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
- Simply Wall St.•2 months ago
Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathizeRead More...
- Business Wire•2 months ago
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14
The Company Will Host a Conference Call at 8:30am ET
- Business Wire•2 months ago
Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today shared additional clinical results from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, boys with Duchenne muscular dystrophy (DMD) treated with edasalonexent on average grew in line with the growth of unaffected boys in the same age range.
- Business Wire•2 months ago
Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President, Global Pharmaceutical Development and Operations at Celgene. “Joanne brings deep knowledge of pharmaceutical development and operations to Catabasis, and we are excited to have her join our board of directors,” said Ken Bate, Chairman of Catabasis’ Board of Directors.
- Business Wire•3 months ago
Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public offering price of $5.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 4,000,000 shares of common stock and warrants to purchase 2,000,000 shares of common stock. Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
- Benzinga•3 months ago
The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
- Business Wire•3 months ago
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering.
- GlobeNewswire•3 months ago
New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•3 months ago
Is Catabasis Pharmaceuticals, Inc.’s (NASDAQ:CATB) CEO Overpaid Relative To Its Peers?
Jill Milne has been the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) since 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- Zacks•3 months ago
Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Catabasis Pharmaceuticals, Inc. (CATB) has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•3 months ago
Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?
Is (CATB) Outperforming Other Medical Stocks This Year?
- Zacks•4 months ago
Agenus (AGEN) Surges: Stock Moves 9.4% Higher
Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
